The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
SchmittelA.SebastianM.Fischer von WeikersthalL.A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol.2011; 22(8): 1798–1804.
2.
SchmittelA.von WeikersthalL.SebastianM.A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol.2006; 17(4): 663–667.
3.
KinoshitaA.FukudaM.SodaH.Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. Br J Cancer.2006; 94(9): 1267–1271.
4.
SohnJ.H.ChoiH.J.ChangJ.A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. Lung Cancer.2006; 54(3): 365–370.
5.
LaackE.ThomI.KrullA.A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC). Lung Cancer.2007; 57(2): 181–186.
6.
HiroseT.HorichiN.OhmoriT.Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer.2003; 40(3): 333–338.
7.
HermesA.BergmanB.BremnesR.Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase III trial. J Clin Oncol.2008; 26(26): 4261–4267.
8.
ChenG.HuynhM.FehrenbacherL.Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol.2009; 27(9): 1401–1404.
9.
KimY.S.ParkS.H.KyungS.Y.Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer. Med Oncol.2011; 28(1): 342–350.
10.
OkishioK.MioT.KawaharaM.A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: A multicenter phase II trial JMTO LC02-02. Jpn J Clin Oncol.2012; 42(5): 387–393.
11.
MurataY.HiroseT.YamaokaT.Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer. Eur J Cancer.2011; 47(9): 1336–1342.
12.
HornL.ZhaoZ.SandlerA.A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer. Clin Lung Cancer.2011; 12(3): 161–165.
13.
SpigelD.R.GrecoF.A.RubinM.S.Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. Lung Cancer.2012; 77(2): 359–364.
14.
NakaN.KawaharaM.OkishioK.Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer.2002; 37(3): 319–323.
15.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines –Small Cell Lung Cancer. V.2.2014. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed December 6, 2013.
16.
TakedaK.TakifujiN.UejimaH.Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer. Lung Cancer.2002; 38(3): 303–308.
17.
FukudaM.OkaM.SodaH.Phase II study of irinotecan combined with carboplatin in previously untreated non-small cell lung cancer. Cancer Chemother Pharmacol.2004; 54(6): 573–577.
18.
PillotG.ReadW.HennenfentK.A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: Final report. J Thorac Oncol.2006; 1(9): 972–978.
19.
KimH.S.KimJ.H.KimB.Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol.2013; 71(6): 1591–1597.
20.
CheungY.W.CradockJ.C.VishnuvajjalaB.R.FloraK.P.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987; 44(1): 124–130.
21.
HeskethP.J.Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist.1999; 4(3): 191–196.
22.
DuBoisA.VachW.KiechleM.Cramer-GiraudU.MeerpohlH.G.Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. Oncology.1996; 53(suppl 1): 46–50.
23.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(suppl 1): 26–31.
BaschE.PrestrudA.A.HeskethP.J.Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol.2011; 29(31): 4189–4198.
GelingO.EichlerH.G.Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
28.
TerreyJ.P.AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
29.
CarmichaelJ.KeizerH.J.CupissolD.MilliezJ.ScheidelP.SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
30.
de WitR.de BoerA.C.vd LindenG.H.StoterG.SparreboomA.VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19;85(8): 1099–1101.
31.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
32.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
33.
CecchinE.InnocentiF.D'AndreaM.Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol.2009; 27(15): 2457–2465.
34.
InnocentiF.UndeviaS.IyerL.Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol.2004; 22(8): 1382–1388.
35.
AndoY.SakaH.AndoM.Polymorphisms of UDP-glucuronyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res.2000; 60(24): 6921–6926.
36.
RouitsE.Boisdron-CelleM.DumontA.Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Can Res.2004; 10(15): 5151–5159.
37.
PicusJ.MartinM.G. Gastrointestinal complications of chemotherapy. In: PerryM.C., ed. The Chemotherapy Source-book.4th ed.Philadelphia, PA: Lippincott Williams and Wilkins; 2008: 197–208.
38.
MarounJ.A.AnthonyL.B.BlaisN.Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: A consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol.2007; 14(1): 13–20.
39.
BensonA.B.AjaniJ.A.CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
40.
SmithT.J.KhatcheressianJ.LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
ZanottiK.M.MarkhamM.Prevention and management of antineoplastic-induced Hypersensitivity reactions. Drug Safety.2001; 24(10): 767–779.
45.
MarkmanM.KennedyA.WebsterK.Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol.1999; 17(4): 1141–1145.
46.
LenzH.J.Management and preparedness for infusion and hypersensitivity reactions. Oncologist.2007; 12(5): 601–609.
47.
PolyzosA.TsavarisN.KosmasC.Hypersensitivity reactions to carboplatin administration are common but not always severe: A 10-year experience. Oncology.2001; 61(2): 129–133.
48.
KintzelP.E.DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treatment Reviews.1995; 21(1): 33–64.
49.
CalvertA.H.NewellD.R.GumbrellL.A.Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol.1989; 7(11): 1748–1756.
50.
CockcroftD.W.GaultM.H.Prediction of creatinine clearance from serum creatinine. Nephron.1976; 16(1): 31–41.
51.
CathomasR.HarleA.MeadG.M.Glomerular filtration rate (GFR) in patients with stage I testicular seminoma treated with adjuvant carboplatin: A comparison of six formulae compared to a radioisotope gold standard. J Clin Oncol.2007; 25(18 Suppl): abstract 15504.
52.
BoumedienF.ArsenaultY.LeTarteN.Impact of weight and creatinine measurements in carboplatin dosing. J Clin Oncol.2012; 30(15 Suppl): abstract e13027.
53.
EkhartC.RodenhuisS.SchellensJ.H.M.BeijnenJ.H.HuitemaA.D.R.Carboplatin dosing in overweight and obese patients with normal renal function. Does weight matter?Cancer Chemother Pharmacol.2009; 64(1): 115–122.
54.
HerringtonJ.D.TranH.T.RiggsM.W.Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥ 27 or cachexia. Cancer Chemother Pharmacol.2006; 57(2): 241–247.
55.
DevineB.J.Gentamycin therapy. Drug Intell Clin Pharm.1974; 8: 650–655.
56.
KaagD.Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors. Lung Cancer.2013; 79(1): 54–58.
57.
HerringtonJ.D.TranH.T.RiggsM.W.Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥ 27 or cachexia. Cancer Chemother Pharmacol.2006; 57(2): 241–247.
